The anti-inflammatory potential of nicotinamide (vitamin B3) in JIA: modulating Treg numbers and function

A single B vitamin -- one you can buy at any pharmacy -- is showing up in peer-reviewed immunology research as a potential tool for reshaping the immune dysfunction that drives juvenile idiopathic arthritis (JIA). That is a claim worth slowing down on, because the supplement world moves faster than the evidence does, and this area of research deserves more precision than it typically gets.

A 2025 study indexed on PubMed (PMID 42316370) examined the anti-inflammatory potential of nicotinamide (a form of vitamin B3) in JIA specifically through its effects on regulatory T cells (Tregs) -- the immune system's internal braking mechanism. The findings are preliminary. They are also genuinely interesting, and they connect to a broader shift in how clinicians think about NAD+ biology, immune regulation, and functional medicine. At NoMi Beach Health (NBH), we think it is worth explaining clearly.

What JIA actually is -- and why Tregs matter

Juvenile idiopathic arthritis is the most common chronic inflammatory arthritis in children under 16. "Idiopathic" means no single cause has been identified, though the immune system is clearly misfiring. In several JIA subtypes, the joints become chronically inflamed because the immune system fails to turn itself down after responding to a perceived threat (Ravelli A, Martini A. Lancet, 2007 -- https://pubmed.ncbi.nlm.nih.gov/17336654/).

Regulatory T cells are supposed to prevent that. Their job is to suppress excessive immune activation -- to act as a check on the T cells that drive inflammation. In JIA, Treg numbers are often reduced in the blood, and the Tregs that remain may not function properly (Coombs J et al. Arthritis Res Ther, 2021 -- https://pubmed.ncbi.nlm.nih.gov/34454591/). When the brakes fail, the inflammatory response keeps running.

This is why the immune checkpoint angle matters. If you could restore Treg numbers or improve how well they function, you might dampen the inflammation driving joint damage -- ideally without the side-effect burden of biologics or long-term immunosuppressants. That is the hypothesis driving research into nicotinamide in JIA.

What nicotinamide does inside the immune system

Nicotinamide (also called niacinamide) is one of two primary forms of vitamin B3. It is distinct from niacin (nicotinic acid) in that it does not trigger the uncomfortable skin flushing that niacin is known for, because it acts through different receptor pathways.

Both forms are precursors to NAD+ -- nicotinamide adenine dinucleotide -- a coenzyme found in every cell and essential for energy metabolism. But NAD+ also feeds a family of enzymes called sirtuins and PARPs that regulate DNA repair, inflammation signaling, and gene expression in immune cells (Cantó C et al. Nat Rev Mol Cell Biol, 2015 -- https://pubmed.ncbi.nlm.nih.gov/25994094/).

Sirtuins, particularly SIRT1, have a well-documented role in dampening NF-κB-driven inflammation (Kauppinen A et al. Cell Signal, 2013 -- https://pubmed.ncbi.nlm.nih.gov/23707600/). NAD+ availability directly affects SIRT1 activity. This creates a mechanistic bridge: if nicotinamide raises intracellular NAD+, it could enhance SIRT1 function, which in turn could support Treg stability and suppressive capacity.

The 2025 paper examined this pathway in the JIA context. The authors found that nicotinamide treatment was associated with changes in Treg populations -- specifically, expansion of Treg numbers and evidence of improved suppressive function -- that are biologically plausible given the NAD+-sirtuin-immune axis. This is not the same as a clinical trial showing symptom reduction, and we will get to that distinction. But the mechanism is grounded in established molecular biology, not speculation.

Regulatory T cells: what the research actually shows

To understand why the 2025 findings matter, it helps to know what "regulatory T-cell dysfunction" looks like in practice and why it is so hard to target.

Tregs express a transcription factor called FOXP3, which is required for their identity and suppressive function (Vignali DAA et al. Nat Rev Immunol, 2008 -- https://pubmed.ncbi.nlm.nih.gov/18566595/). In inflamed joints, the environment can destabilize FOXP3 expression, meaning Tregs that migrate to the joint may lose their suppressive identity and effectively switch sides -- contributing to inflammation rather than containing it. This Treg plasticity problem is a major reason why simply counting Tregs in the blood does not tell you the full story of immune regulation in JIA.

What the nicotinamide research suggests is that NAD+-dependent pathways may help stabilize FOXP3 expression and Treg identity, particularly in inflamed environments. Sirtuins are involved in deacetylating FOXP3 in ways that affect its stability. When NAD+ is depleted -- which happens during sustained inflammation -- SIRT1 activity drops and FOXP3 stability can suffer. Restoring NAD+ availability through nicotinamide could, in theory, help Tregs maintain their suppressive phenotype even in the presence of inflammatory signals.

This is the level at which the research currently sits: mechanistically compelling, early-stage, not yet a treatment. Clinicians following this field will recognize the pattern -- NAD+ biology keeps appearing in inflammation research in ways that are too consistent to dismiss and too early to overstate. We have written about NAD+ therapy and its cellular role at [/blog/nad-therapy-cellular-rejuvenation], and the immune dimension of this story fits within that framework.

What clinicians look for before acting on early research

Here is where we want to be direct with you, because the supplement industry is already ahead of the evidence on this.

The 2025 study is an important mechanistic and early clinical signal. It is not a randomized controlled trial showing that nicotinamide reduces JIA disease activity scores, reduces joint erosion on imaging, or allows children to taper off biologics. Those trials do not yet exist. The American College of Rheumatology's 2019 guidelines for JIA treatment -- which remain the standard of care -- do not include nicotinamide as a recommended therapy (Ringold S et al. Arthritis Care Res, 2019 -- https://pubmed.ncbi.nlm.nih.gov/31021516/).

What this research does is identify a plausible target and a testable intervention. That is genuinely valuable. It gives researchers a direction and gives clinicians a rationale for watching the space carefully. It does not give anyone a reason to replace a child's methotrexate or etanercept with a B vitamin without clinical supervision.

The safety profile of nicotinamide at doses used in research is generally favorable. A systematic review found that doses used in clinical trials -- typically in the range of 1 to 3 g/day in adults -- were well tolerated, though doses above that range have been associated with hepatotoxicity in some reports (Knip M et al. Diabetologia, 2000 -- https://pubmed.ncbi.nlm.nih.gov/11126400/). Pediatric dosing is a separate calculation requiring clinician oversight.

For adults reading this in the context of their own inflammatory conditions -- rheumatoid arthritis, psoriatic arthritis, systemic lupus, undifferentiated inflammatory disease -- the Treg-NAD+ axis is relevant to adult immunology as well. But the specific data here is in a pediatric population, and extrapolation requires care.

How this connects to NAD+ biology in functional medicine

At NBH, we approach NAD+ precursor therapy -- whether through IV NAD+, nicotinamide riboside (NR), or nicotinamide mononucleotide (NMN) -- as a tool with real biological rationale and an honest evidence base that is still growing (Verdin E. Science, 2015 -- https://pubmed.ncbi.nlm.nih.gov/26785480/).

The JIA research adds an immune-regulatory dimension to a story that has mostly been told through the lens of mitochondrial energy, aging, and neuroprotection. If NAD+ availability shapes Treg function, then the chronic NAD+ depletion that comes with sustained inflammation, metabolic stress, or aging is not just an energy problem -- it is potentially an immune regulation problem.

This does not mean every person with an inflammatory condition should immediately start NAD+ precursor supplementation. It means the question "what is your NAD+ status and what might be driving it down" is a more interesting clinical question than it was a decade ago. It is one we incorporate into functional medicine evaluations where it is relevant. You can read more about how we approach that layer of care at [/blog/functional-wellness-without-the-woo].

For context, we have also written about NAD+ precursor research in the context of mitochondrial dysfunction at [/blog/hm568-enhances-nad-biosynthesis-to-ameliorate-mitochondrial-dysfunction-and-neur], which covers overlapping metabolic ground from a different angle.

What this means in a real clinical conversation

If you are a parent of a child with JIA, the honest answer is: this research is not ready to change your child's treatment plan, but it is worth knowing about and worth discussing with your pediatric rheumatologist. The mechanism is plausible, the safety profile is reasonable, and the research is active. A clinician who follows this literature will be able to help you evaluate it in context.

If you are an adult managing an inflammatory condition and looking for evidence-based functional medicine support alongside your rheumatology care, the Treg-NAD+ connection is one piece of a larger picture. Dr. Jezwah Harris (NP, JD, MBA, FNP-BC, MEP-C) takes a systematic approach to that picture: labs first, mechanism second, intervention only when the rationale is clear and the monitoring is in place.

What we do not do is sell nicotinamide as an "immune optimizer" or suggest that a B vitamin will replace immunosuppression. The evidence does not support that framing, and our voice does not either. Honest beats hyped -- in inflammatory disease as in everything else.

If you want to understand where functional medicine tools like NAD+ precursors, dietary support, and immune-regulation strategies fit within a broader plan for an inflammatory condition, the right starting point is a comprehensive new-patient evaluation, not a supplement order.

---

Ready to look at the whole picture? Our functional medicine evaluations at NBH start with the right labs and a real conversation -- not a protocol built before we know what you need. Visit our functional medicine services page to learn what a first visit looks like, or call us at (786) 744-5152. Dr. Harris will review your case personally.